These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 15871554

  • 1. Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive.
    Keam SJ, Wagstaff AJ.
    Treat Endocrinol; 2003; 2(1):49-70. PubMed ID: 15871554
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of the combined oral contraceptive ethinylestradiol/drospirenone (Yasmin) in healthy Chinese women: a randomized, open-label, controlled, multicentre trial.
    Guang-Sheng F, Mei-Lu B, Li-Nan C, Xiao-Ming C, Zi-Rong H, Zi-Yan H, Xiao-Ping J, Jian L, Shu-Ying W, Cheng-Liang X, Zheng-Ai X, Tian-Fu Y.
    Clin Drug Investig; 2010; 30(6):387-96. PubMed ID: 20201608
    [Abstract] [Full Text] [Related]

  • 3. Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women: a randomized, single-blind, parallel-group, multicentre study.
    Kelly S, Davies E, Fearns S, McKinnon C, Carter R, Gerlinger C, Smithers A.
    Clin Drug Investig; 2010; 30(5):325-36. PubMed ID: 20384388
    [Abstract] [Full Text] [Related]

  • 4. Experiences with Yasmin: the acceptability of a novel oral contraceptive and its effect on well-being.
    Mansour D.
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():35-41; discussion 42-3. PubMed ID: 12659405
    [Abstract] [Full Text] [Related]

  • 5. Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study.
    Endrikat J, Düsterberg B, Ruebig A, Gerlinger C, Strowitzki T.
    Contraception; 1999 Nov; 60(5):269-74. PubMed ID: 10717778
    [Abstract] [Full Text] [Related]

  • 6. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen.
    Parsey KS, Pong A.
    Contraception; 2000 Feb; 61(2):105-11. PubMed ID: 10802275
    [Abstract] [Full Text] [Related]

  • 7. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
    Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R.
    J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629
    [Abstract] [Full Text] [Related]

  • 8. The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being.
    Boschitsch E, Skarabis H, Wuttke W, Heithecker R.
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():34-40. PubMed ID: 11246600
    [Abstract] [Full Text] [Related]

  • 9. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles.
    Gaspard U, Endrikat J, Desager JP, Buicu C, Gerlinger C, Heithecker R.
    Contraception; 2004 Apr; 69(4):271-8. PubMed ID: 15033400
    [Abstract] [Full Text] [Related]

  • 10. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A, De Leo V.
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [Abstract] [Full Text] [Related]

  • 11. A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30 μg/drospirenone 3 mg administered in a 21/7 regimen versus ethinylestradiol 20 μg/drospirenone 3 mg administered in a 24/4 regimen.
    Marr J, Gerlinger C, Kunz M.
    Eur J Obstet Gynecol Reprod Biol; 2012 May; 162(1):91-5. PubMed ID: 22391750
    [Abstract] [Full Text] [Related]

  • 12. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea.
    van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R.
    Cutis; 2002 Apr; 69(4 Suppl):2-15. PubMed ID: 12096825
    [Abstract] [Full Text] [Related]

  • 13. Multicenter trial of two monophasic oral contraceptives containing 30 mcg ethinylestradiol and either desogestrel or gestodene in Thai women.
    Koetsawang S, Charoenvisal C, Banharnsupawat L, Singhakovin S, Kaewsuk O, Punnahitanont S.
    Contraception; 1995 Apr; 51(4):225-9. PubMed ID: 7796587
    [Abstract] [Full Text] [Related]

  • 14. Cycle control and bleeding pattern of a 24/4 regimen of drospirenone 3 mg/ethinylestradiol 20 μg compared with a 21/7 regimen of desogestrel 150 μg/ethinylestradiol 20 μg: a pooled analysis.
    Anttila L, Neunteufel W, Petraglia F, Marr J, Kunz M.
    Clin Drug Investig; 2011 Apr; 31(8):519-525. PubMed ID: 21721590
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone.
    Huber J, Foidart JM, Wuttke W, Merki-Feld GS, The HS, Gerlinger C, Schellschmidt I, Heithecker R.
    Eur J Contracept Reprod Health Care; 2000 Mar; 5(1):25-34. PubMed ID: 10836660
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters.
    Douxfils J, Klipping C, Duijkers I, Kinet V, Mawet M, Maillard C, Jost M, Rosing J, Foidart JM.
    Contraception; 2020 Dec; 102(6):396-402. PubMed ID: 32956694
    [Abstract] [Full Text] [Related]

  • 17. Yasmin: the reason why.
    Thorneycroft IH.
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():13-8; discussion 42-3. PubMed ID: 12659402
    [Abstract] [Full Text] [Related]

  • 18. Transfer of drospirenone to breast milk after a single oral administration of 3 mg drospirenone + 30 microg ethinylestradiol to healthy lactating women.
    Blode H, Foidart JM, Heithecker R.
    Eur J Contracept Reprod Health Care; 2001 Sep; 6(3):167-71. PubMed ID: 11763981
    [Abstract] [Full Text] [Related]

  • 19. Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris.
    Fenton C, Wellington K, Moen MD, Robinson DM.
    Drugs; 2007 Sep; 67(12):1749-65. PubMed ID: 17683173
    [Abstract] [Full Text] [Related]

  • 20. Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive.
    Anttila L, Kunz M, Marr J.
    Contraception; 2009 Nov; 80(5):445-51. PubMed ID: 19835718
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.